Literature DB >> 16387099

Lambda light chain deposition disease in a renal allograft.

N D Tanenbaum1, D N Howell, J P Middleton, R F Spurney.   

Abstract

Light chain deposition disease (LCDD) of the kidney is characterized by deposition of monoclonal light chains predominantly in glomeruli and in tubular basement membranes. The disease is frequently associated with a lymphoproliferative disorder, and the majority of cases are caused by deposition of kappa light chains. Although the occurrence of de novo multiple myeloma after renal transplantation is uncommon, there are several reports of LCDD involving renal allografts, either de novo or in patients with a diagnosis of LCDD prior to transplantation. To the best of our knowledge, all previously described cases in allografts have been in patients with kappa chain deposition. The relative importance of intrinsic properties of the kidney in predisposing to either kappa or lambda light chain deposition is not known. We present a case of LCDD caused by deposition of lambda light chains in a patient who received a cadaveric renal transplant.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16387099     DOI: 10.1016/j.transproceed.2005.10.030

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.

Authors:  Camille Cohen; Bruno Royer; Vincent Javaugue; Raphael Szalat; Khalil El Karoui; Alexis Caulier; Bertrand Knebelmann; Arnaud Jaccard; Sylvie Chevret; Guy Touchard; Jean-Paul Fermand; Bertrand Arnulf; Frank Bridoux
Journal:  Kidney Int       Date:  2015-07-15       Impact factor: 10.612

2.  Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules.

Authors:  Jonathan E Phipps; Daniel P Kestler; James S Foster; Stephen J Kennel; Robert Donnell; Deborah T Weiss; Alan Solomon; Jonathan S Wall
Journal:  Exp Hematol       Date:  2010-07-14       Impact factor: 3.084

3.  Long-term reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous stem cell transplantation.

Authors:  Tomás J González-López; Lourdes Vázquez; Teresa Flores; Jesus Fernando San Miguel; Ramon García-Sanz
Journal:  Clin Pract       Date:  2011-11-23

Review 4.  Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature.

Authors:  Raphaël Kormann; Hélène François; Thibault Moles; Jacques Dantal; Nassim Kamar; Karine Moreau; Thomas Bachelet; Anne-Elisabeth Heng; Antoine Garstka; Charlotte Colosio; Didier Ducloux; Johnny Sayegh; Benjamin Savenkoff; Denis Viglietti; Rebecca Sberro; Eric Rondeau; Julie Peltier
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

5.  A de novo monoclonal immunoglobulin deposition disease in a kidney transplant recipient: a case report.

Authors:  Benjamin Savenkoff; Perrine Aubertin; Marc Ladriere; Cyril Hulin; Jacqueline Champigneulle; Luc Frimat
Journal:  J Med Case Rep       Date:  2014-06-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.